Meeting
2017 ASCO Annual Meeting
Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.
Authors
Kaitlin M. Peace
San Antonio Military Medical Center, San Antonio, TX
Kaitlin M. Peace , Elizabeth Ann Mittendorf , Sonia A. Perez , Panagiotis Tzonis , Nikolaos Fragkiskos Pistamaltzian , Eleftheria A Anastasopoulou , Timothy J. Vreeland , Diane F Hale , Guy T Clifton , Jennifer Keating Litton , Eric von Hofe , Alexandros Ardavanis , Michael Papamichail , George Earl Peoples
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT00524277
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3088)
DOI
10.1200/JCO.2017.35.15_suppl.3088
Abstract #
3088
Poster Bd #
183
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
First Author: Elizabeth Ann Mittendorf
Poster
2012 Breast Cancer Symposium
Early efficacy analysis of the AE37 vaccine in patients with HER2 low-expressing and triple-negative breast cancer.
First Author: Elizabeth Mittendorf
Poster
2011 ASCO Annual Meeting
Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone.
First Author: A. K. Sears
Poster
2013 ASCO Annual Meeting
Safety and efficacy of the HER2-derived GP2 peptide vaccine in combination with trastuzumab for breast cancer patients in the adjuvant setting.
First Author: Ritesh Patil